Compounds as cannabinoid receptor ligands

A compound according to formula (I),

• or a pharmaceutically acceptable salt, solvates, salt of a solvate, or solvate of a salt thereof, wherein
• R1 is alkyl, haloalkyl, G1, —(CRxRy)m-G1, or —N(R1a)(Rz);
• Rz is alkyl, haloalkyl, G2, —(CRxRy)m-G2, —(CRxRy)n—ORza, —(CRxRy)n—N(Rza)Rzb) —(CRxRy)m—C(O)O(Rza), —(CRxRy)m—C(O)Rza, —(CRxRy)m—C(O)N(Rza)(Rzb), —(CRxRy)m—S(O))2O(Rza), —(CRxRy)m—S(O))2Rza, —(CRxRy)m—S(O))2N(Rza)(Rzb), or —(CRxRy)m—CN;
• G1 and G2, at each occurrence, are each independently aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl;
• wherein each ring is independently unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, —NO2, —CN, halogen, oxo, —ORe, —O—(CRjRk)n—N(Rw)2, —OC(O)Re, —SRe, —SF5, —S(O))Rf, —S(O))2Rf, —S(O))2N(Re)(Rg), —N(Re)(Rg), —N(Rg)C(O)Re, —N(Rg)C(O)O(Rf), —N(Rg)S(O)2Rf, —N(Rg)C(O)N(Re)(Rg), —N(Rg)S(O)2N(Re)(Rg), —C(O)Re, —C(O)O(Re), —C(O)N(Re)(Rg), alkoxyalkenyl, hydroxyalkenyl, haloalkyl, —(CRjRk)q—CN, —(CRjRk)q—ORe, —(CRjRk)q—OC(O)Re, —(CRjRk)q—SRe, —(CRjRk)q—S(O))Rf, —(CRjRk)q—S(O)2Rf, —(CRjRk)q—N(Re)(Rg), —(CRjRk)q—N(Rg)C(O)Re, —(CRjRk)q—N(Rg)S(O))2Rf, —(CRjRk)q—N(Rg)C(O)N(Re)(Rg), —(CRjRk)q—N(Rg)S(O)2N(Re)(Rg), —(CRjRk)q—C(O)Re, —(CRjRk)q—C(O)O(Re), —(CRjRk)q—C(O)N(Re)(Rg), —C(Rw)═N—ORw, and morpholinyl;
• Ring A represents formula (a), (b), (c), or (d)
• R21, R22, R23, and R24 are -alkylene-G3 wherein G3, at each occurrence, is independently furanyl, oxazolyl, isoxazolyl, oxadiazolyl, or a 4-, 5-, 6-, 7-, 8-, or 9-membered monocyclic heterocycle containing zero or one double bond, one or two oxygen, and zero or one nitrogen as ring atoms, wherein two non-adjacent atoms of said monocyclic heterocycle is optionally linked by an alkenylene bridge of 2, 3, or 4 carbon atoms, or optionally linked by an alkylene bridge of 1, 2, 3, or 4 carbon atoms;
• each G3 ring is optionally fused with a monocyclic ring selected from the group consisting of benzo, cycloalkyl, cycloalkenyl, heterocycle, and heteroaryl;
• and each G3 is independently unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from the group consisting of oxo, alkyl, halogen, —OH, —O(alkyl), —O(haloalkyl), and haloalkyl;
• Rw, at each occurrence, is independently hydrogen or alkyl;
• R3, R6, R7, R8, R9, R11, and R12 are each independently hydrogen, alkyl, alkenyl, alkynyl, —NO2, —CN, halogen, —ORa, —N(Ra)(Rb), —C(O)Ra, —C(O)O(Ra), haloalkyl —(CRcRd)p—ORa, —(CRcRd)p—N(Ra)(Rb), —(CRcRd)p—C(O)Ra, —(CRcRd)p—C(O)O(Ra), cycloalkyl, cycloalkenyl, or heterocycle;
• R4 and R5, are each independently hydrogen, alkyl, alkenyl, alkynyl, —NO2, —CN, halogen, —ORa, —N(Ra)(Rb), —C(O)Ra, —C(O)O(Ra), haloalkyl, —(CRcRd)p—ORa, —(CRcRd)p—N(Ra)(Rb), —(CRcRd)p—C(O)Ra, —(CRcRd)p—C(O)O(Ra), cycloalkyl, cycloalkenyl, or heterocycle;
• or R4 and R5, together with the carbon atoms to which they are attached, form a monocyclic cycloalkyl ring which is optionally further substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, alkyl, haloalkyl, and oxo;
• Ra, Rb, R1a, Rza, and Rzb, at each occurrence, are each independently hydrogen, alkyl, or haloalkyl;
• Rx, at each occurrence, is independently hydrogen, halogen, alkyl, haloalkyl, or benzyl;
• Ry, Rc, and Rd, at each occurrence, are each independently hydrogen, halogen, alkyl, or haloalkyl;
• X1 and X2 are independently O, S, or N(R10) wherein R10 is alkyl, alkoxyalkyl, haloalkoxyalkyl, or haloalkyl;
• the cycloalkyl, cycloalkenyl, and heterocycle, as represented by R3, R4, R5, R6, R7, R8, R9, R11, and R12 are each independently unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, —NO2, —CN, halogen, oxo, —ORe, —OC(O)Re, —SRe, —S(O))Rf, —S(O))2Rf, —(O)2N(Re)(Rg), —N(Re)(Rg), —N(Rg)C(O)Re, —N(Rg)S(O)2Rf, —N(Rg)C(O)N(Re)(Rg), N(Rg)S(O)2N(Re)(Rg), —C(O)Re, —C(O)O(Re), —C(O)N(Re)(Rg), haloalkyl, —(CRjRk)q—CN, —(CRjRk)q—ORe, —(CRjRk)q—OC(O)Re, —(CRjRk)q—SRe, —(CRjRk)q—S(O))Rf, —(CRjRk)q—S(O)2Rf, —(CRjRk)q—N(Re)(Rg), —(CRjRk)q—N(Rg)C(O)Re, —(CRjRk)q—N(Rg)S(O))2Rf, —(CRjRk)q—N(Rg)C(O)N(Re)(Rg), —(CRjRk)q—N(Rg)S(O))2N(Re)(Rg), —(CRjRk)q—C(O)Re, —(CRjRk)q—C(O)O(Re), and —(CRjRk)q—C(O)N(Re)(Rg);
• Re and Rg, at each occurrence, are each independently hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, aryl, heteroaryl, haloalkoxyalkyl, or haloalkyl;
• wherein the aryl, the heteroaryl, the cycloalkyl, and the heterocycle moieties, by itself or as part of the substituents of Re and Rg, are each independently unsubstituted or substituted with 1, 2, 3, 4, 5 or 6 substituents selected from the group consisting of alkyl, halogen, haloalkyl, hydroxy, oxo, ═N—O(H), ═N—O(alkyl), and alkoxy;
• Rf, at each occurrence, is independently alkyl or haloalkyl;
• Rj and Rk, at each occurrence, are each independently hydrogen, halogen, alkyl, or haloalkyl;
• m, p, and q, at each occurrence, are each independently 1, 2, 3, or 4;
• and
• n is 2, 3 or 4.